was approved by the EC in November 2024 and by the Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025 for the treatment of patients with Wet AMD, Visual Impairment due to Macular Oedema Secondary to RVO, Visual Impairment due...
At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr. Jarrod Frizzell of The Christ Hospital (Cincinnati, OH) presented real-world studies¹,² demonstrating that the EggNest™ Complete Radiation Protection System from Egg...
pharmaceutical and biotech industries from development to delivery. The 20,000-square-foot expansion, which began in Q4 2025 and is expected to be finalized in 2026, will significantly strengthen Alcami's analytical capabilities in support of...
and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2025, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 875 companies...
amyloid-beta (Aβ). Lecanemab has been approved in 50 countries and is under regulatory review in 8 countries. In January 2025, the supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was...
certification for compliance to the In Vitro Diagnostic Regulation (IVDR) in the European Union. “This week at ASHI 2025, we will highlight our continued investment in creating life changing solutions that allow transplant patients to thrive,” said...
disease, and kidney disease. Its lead asset, ENBUMYST™ (bumetanide nasal spray), was approved by the FDA on September 12, 2025 and is designed to offer rapid, reliable diuresis outside the hospital setting. About U.S. Heart and Vascular (USHV)...
comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s. In July 2025, the U.S. Food and Drug Administration (FDA) approved a new indication for KERENDIA to treat adult patients with heart failure...
results following treatment with plixorafenib. The data are being presented at the American Thyroid Association® (ATA) 2025 Annual Meeting, taking place September 10-14, 2025 in Scottsdale. “These results presented at ATA 2025 demonstrate durable...
System at the upcoming Pulmonary Hypertension Professional Network (PHPN) Symposium, taking place September 18–20, 2025, in Seattle, Washington. The presentation will feature preclinical pharmacokinetic and safety data for the TRX-248 Transdermal...
the use of LUMRYZ as a narcolepsy treatment will be presented in one oral presentation and 16 posters at World Sleep 2025, taking place September 5-10, in Singapore. "LUMRYZ's novel once-nightly delivery system means patients do not have to worry...
data were presented today during a late-breaking presentation (OA06.03) and included as part of the press program at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC25). Ifinatamab...
need, announced that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9, 2025, titled “Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B Virus...
and approved by leading global regulatory agencies including the USFDA, PMDA (Japan), and CDSCO (India). As of March 2025, Sai Life Sciences’ manufacturing units had undergone over 75 customer audits in the past three years, reflecting its...
virkningsmekanisme. Studiet forventes at inkludere 32 patienter, hvor den første patient forventes inkluderet i 4. kvartal 2025. ”Myndighedsgodkendelsen af vores RNX-011-studie er en afgørende kommerciel milepæl for Pharma Equity Group. Vi tager nu...
FIP world congress 2025, themed “Pharmacy Forward: Performance, Collaboration, and Health Transformation,” aims to explore the evolving role of the pharmacy profession in the context of modern healthcare challenges. FIP world congress 2025, themed...
In the IIT, the patient began with a baseline hemoglobin level of 67.3 g/L. Following CS-101 treatment in February 2025, she achieved rapid hematopoietic recovery, with neutrophil engraftment in 13 days and platelet counts surpassing 50×10⁹/L in 21...
the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2025 interim results and major business updates. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated:...
The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected pharmaceutical manufacturing shows in Singapore for pharmaceutical and biomanufacturing professionals. The ISPE Singapore Affiliate Conference &...
Breakthrough Data Validates its Dual-immune Activation Mechanism, Stepwise Development in Multiple Tumor Types: At ASCO 2025, Phase 1b/2 results demonstrated meaningful and durable clinical activity in areas of high unmet need, including...
